Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children
- First Online:
- Cite this article as:
- Lundh, M., Christensen, D.P., Damgaard Nielsen, M. et al. Diabetologia (2012) 55: 2421. doi:10.1007/s00125-012-2615-0
- 1.7k Downloads
Histone deacetylases (HDACs) are promising pharmacological targets in cancer and autoimmune diseases. All 11 classical HDACs (HDAC1–11) are found in the pancreatic beta cell, and HDAC inhibitors (HDACi) protect beta cells from inflammatory insults. We investigated which HDACs mediate inflammatory beta cell damage and how the islet content of these HDACs is regulated in recent-onset type 1 diabetes.
The rat beta cell line INS-1 and dispersed primary islets from rats, either wild type or HDAC1–3 deficient, were exposed to cytokines and HDACi. Molecular mechanisms were investigated using real-time PCR, chromatin immunoprecipitation and ELISA assays. Pancreases from healthy children and children with type 1 diabetes were assessed using immunohistochemistry and immunofluorescence.
Screening of 19 compounds with different HDAC selectivity revealed that inhibitors of HDAC1, -2 and -3 rescued INS-1 cells from inflammatory damage. Small hairpin RNAs against HDAC1 and -3, but not HDAC2, reduced pro-inflammatory cytokine-induced beta cell apoptosis in INS-1 and primary rat islets. The protective properties of specific HDAC knock-down correlated with attenuated cytokine-induced iNos expression but not with altered expression of the pro-inflammatory mediators Il1α, Il1β, Tnfα or Cxcl2. HDAC3 knock-down reduced nuclear factor κB binding to the iNos promoter and HDAC1 knock-down restored insulin secretion. In pancreatic sections from children with type 1 diabetes of recent onset, HDAC1 was upregulated in beta cells whereas HDAC2 and -3 were downregulated in comparison with five paediatric controls.
These data demonstrate non-redundant functions of islet class I HDACs and suggest that targeting HDAC1 and HDAC3 would provide optimal protection of beta cell mass and function in clinical islet transplantation and recent-onset type 1 diabetic patients.
KeywordsAutoimmunityCytokinesEpigeneticsHDACHDAC1HDAC2HDAC3InflammationNFκBType 1 diabetes
Histone deacetylase inhibitors
Multiplicity of infection
Nuclear factor κB
Small hairpin RNA
Beta cell function in type 1 diabetes of recent onset can be preserved by controlling the autoimmune process with the potent T cell immunosuppressant ciclosporin, but clinical use of this drug is prohibited by the need for long-term administration and the ensuing adverse effects . Short courses of anti-CD3 or anti-CD20 antibodies with specific actions on T or B lymphocyte functions, respectively, preserve beta cell function in recent-onset type 1 diabetes, but the effects are transient [2, 3], and depletion of T and B cells increases the risk of developing progressive multifocal leucoencephalopathy . There is therefore a need for safe, preferably orally administered, drugs that can effectively control islet inflammation.
Orally active and clinically well-tolerated broad inhibitors of histone deacetylases (HDACs), a class of enzymes that catalyse the deacetylation of cytosolic and nuclear proteins, including histones and transcription factors such as nuclear factor κB (NFκB) [5, 6], have been developed for malignant disorders at high doses . Recently, these compounds have shown promise in lower doses as potent and safe anti-inflammatory drugs in autoimmune diseases such as systemic-onset juvenile idiopathic arthritis .
HDACs are grouped into class I (HDAC1, -2, -3 and -8), class IIa (HDAC4, -5, -7 and -9), class IIb (HDAC6 and -10) and class IV HDACs (HDAC11) . Class I and IIb HDACs are ubiquitously produced whereas class IIa and IV are more tissue restricted. Among the class I HDACs, HDAC1, -2 and -8 were believed to reside in the nucleus whereas HDAC3 is also found in the cytoplasm . However, recently the cytosolic localisation of HDAC1 and -2 has been demonstrated under pathologic conditions  and during development . Class II and IV HDACs shuttle between the nucleus and cytoplasm .
All 11 classical HDACs are found in pancreatic beta cells in vitro , and beta cell levels of these enzymes are differentially regulated by exposure to IL-1 and IFNγ, key pro-inflammatory cytokines involved in inflammatory beta cell failure and destruction in type 1 diabetes . HDAC inhibitors (HDACi) prevent cytokine-induced beta cell demise in vitro and in animal models of type 1 diabetes [14, 15]. However, it is unknown which HDACs mediate inflammatory beta cell destruction in cytokine-exposed beta cells and how HDAC1−3 are regulated in the islets of patients with type 1 diabetes. Here we used pharmacological inhibitors and small hairpin RNA (shRNA)-mediated transient and stable knock-down to reveal which HDACs mediate inflammatory beta cell damage, and we also studied human pancreatic sections to understand the regulation of these HDACs in children with recent-onset type 1 diabetes.
Cytokines and HDACi
Mouse IL-1β was from BD Pharmingen (Erembodegem, Belgium) and rat IFNγ from R&D Systems (Oxford, UK). ITF compounds were provided in coded form from Italfarmaco (Cinisello Balsamo, Italy). LAQ842, vorinostat and PCI24781 were from Selleck Chemicals (Houston, TX, USA), Helminthosporium carbonum (HC) toxin and PCI34051 were from Sigma-Aldrich (St Louis, MO, USA) and CI-994 was from Exclusive Chemistry Ltd (Obninsk, Russia).
pMD2.G (12259) and psPAX2 (12260) were from Tronolab (Lausanne, Switzerland). The empty vector (pLKO.1) was from Sigma-Aldrich. The vector plasmids were from Sigma-Aldrich (HDAC1: TRCN0000229438, TRCN0000039400) and GeneCopoeia (Rockville, MD, USA) (HDAC2: RSH054257-1, RSH054257-4; HDAC3: RSH051653-4, RSH051653-2).
INS-1 cells were a gift from C. Wollheim, Department of Cell Physiology and Metabolism, University Medical Center, Geneva, Switzerland , and were maintained in complete medium as described . At the initiation of experiments, medium was changed, and HDACi or vehicle were added 1 h before cytokine exposure.
The 293 FT cells (Invitrogen, Taastrup, Denmark) were maintained and prepared for transfection in accordance with the supplier’s manual. HTB-9 cells (ATCC, Manassas, VA, USA) were maintained in complete medium without β-mercaptoethanol and cultured at 37°C in a humidified atmosphere containing 5% CO2.
Lentivirus production and transduction
Plasmids were transformed (C7373-03, Invitrogen), amplified and purified (Fischer Scientific, Slangerup, Denmark). Virus was generated by cotransfection of HEK293 cells with the vector plasmid, psPAX2 plasmid and pMD2.g plasmid using Lipofectamine 2000 (Invitrogen). After 72 h, virus was harvested by ultracentrifugation of the supernatant fraction at 50,000 g for 2 h and the pellet was then resuspended in medium. Titres were determined in HT1080 cells (Invitrogen) according to the supplier’s manual. Stable INS-1 cells were generated by seeding one million cells in 2 ml medium. After 2 days, medium was removed and 800 μl virus-containing medium added (multiplicity of infection [MOI] >10). Medium was replaced with 2 ml complete medium 6 h after transduction. Transduced cells were selected for using 1.5 μg/ml puromycin (Sigma, Poole, UK) for 2 to 3 weeks.
Rat islet isolation, preculture and culture
Primary neonatal rat islets were isolated from outbred Wistar rats (Taconic, Ejby, Denmark), 3 to 6 days old, as previously described  and cultured as previously reported . These experiments were approved by the local veterinary ethics committee.
Rat islet dispersion and lentiviral transduction
Precultured neonatal rat islets were trypsinised to single cells. Fifty thousand (cell death ELISA) or 100,000 (RNA extraction) single cells were seeded in 48 or 12 wells pre-coated with extracellular matrix (ECM), and maintained in 0.5/1.5 ml RPMI 1640 (Gibco, Taastrup, Denmark), supplemented with 2% human serum (Bio Whitaker, Basel, Switzerland), 11.1 mmol/l glucose, 100 U/ml penicillin and 100 μg/ml streptomycin. Dispersed cells were cultured at 37°C in a humidified atmosphere containing 5% CO2. After 48 h medium was removed and replaced with 150 μl (48 wells)/250 μl (12 wells) medium containing Lentivirus (MOI = 10). Virus-containing medium was replaced with 0.5 ml (48 wells)/1.5 ml (12 wells) medium after 6 h. Cytokines were added 72 h after virus transduction.
HTB-9 cells were grown for 2 days beyond 100% confluency followed by one wash with water. Coated wells containing water were stored at 4°C. Wells were washed once before use.
IC50 activity assay
Enzyme activity was measured in duplicate in 384-well plates using the HDAC-Glo I/II Assay (Promega, Madison, WI, USA). For IC50 curves, dilution series of ten different compound concentrations were made in fourfold steps in DMSO. The series were diluted ten times in assay buffer and 5 μl compound was mixed with 5 μl enzyme followed by 10 μl HDAC-Glo Reagent containing substrate. The IC50 for all compounds was determined with seven HDACs (BPS Bioscience, San Diego, CA, USA) using the following concentrations: 0.00625 ng/μl HDAC1; 0.0030 ng/μl HDAC2; 0.00625 ng/μl HDAC3; 0.12 ng/μl HDAC6; 0.10 ng/μl HDAC8; 0.61 ng/μl HDAC10; 3 ng/μl HDAC11. Enzymes were diluted in assay buffer.
Assay Z-factors were: HDAC1, 0.84; HDAC2, 0.79; HDAC3, 0.86; HDAC6, 0.74; HDAC8, 0.84; HDAC10, 0.82; HDAC11, 0.80. All compounds were tested for inhibition of assay components according to assay protocol. Luminescence signal was measured with BioTek Synergy 4 (BioTek, Winooski, VT, USA) after 40 min.
An arbitrary cell index reflecting real-time attachment, morphology and proliferation of INS-1 cells was monitored using the xCELLigence RTCA SP (Roche Diagnostics, Mannheim, Germany) platform. E-plates (96 wells) were pre-coated with poly-d-lysine (Sigma). Fifty microlitres of medium was added per well for background impedance measurement before the addition of 20,000 INS-1 cells in 20 μl medium followed by 30 min incubation at room temperature. The E-plate was inserted into the RTCA and placed at 37°C with 5% CO2. After 24 h, HDACi were added in duplicate in 30 μl medium. After 1 h, cytokines or vehicle were added. Impedance was measured hourly and the AUC of the 48–72 h interval was calculated. Results are depicted as percentage rescue of cells treated with cytokine alone.
Cell death detection by ELISA
Aliquots of 50,000 stably transduced INS-1 cells or 50,000 dispersed rat islet cells were seeded in 48-well plates containing 0.5 ml medium. Cytokine-induced apoptosis was determined as previously described .
One million wild-type or stably transduced INS-1 cells, or 100,000 dispersed rat islet cells, were seeded in six-well plates in 2 ml complete medium or 12-well plates in 1.5 ml medium. RNA purification, cDNA synthesis and real-time PCR were performed as previously described . TaqMan probes were as follows: Hprt1: Rn01318745_g1; iNos (also known as Nos2): Rn00561646_m1; Il1α (also known as Il1a): Rn00566700_m1; Il1β (also known as Il1b): Rn99999009_m1; Cxcl2: Rn00586403_m1; Tnfα (also known as Tnf): Rn99999017_m1; Cxcl10: Rn00594648_m1.
Fifty thousand stably transduced INS-1 cells or 50,000 dispersed rat islet cells were seeded in 48-well plates containing 0.5 ml medium with 11 mmol/l glucose. Cells were exposed to cytokines and accumulated insulin was measured as previously described .
Chromatin immunoprecipitation assay
For the chromatin immunoprecipitation (ChIP) assay, 5,000,000 stably transduced INS-1 cells were exposed to cytokines. At the indicated time points DNA/protein was crosslinked. Lysis buffer was added to cells which were then lifted and transferred to Eppendorf tubes. Samples were sonicated at high intensity for 10 min in pulses of 30 s. p65 was immunoprecipitated as previously described  with 5 μg p65 antibody (sc372-X; Santa Cruz, CA, USA). Immunoprecipitated chromatin was extracted, and the presence of specific DNA co-precipitated with p65 was determined by real-time PCR targeting a proximal and distal p65-binding site in the iNos promoter (see Electronic supplementary material [ESM] Table 1 for primers). Background was assessed by the average signal from two no-gene controls: beta-globin and 1q32A (see ESM Table 1 for primers). AUC was calculated and background signal was subtracted.
Five human pancreases removed at autopsy from patients who had recent-onset type 1 diabetes were selected randomly from a previously described collection . Specimens had been fixed in buffered formalin, unbuffered formol saline or Bouin’s fixative, and they were all paraffin embedded. The selected cohort from which pancreases were obtained consisted of patients with a mean ± SD age of 5.5 ± 1.9 years (range 1–11 years). Controls were five normal pancreases from individuals age-matched to the patients with type 1 diabetes, such that they had a mean ± SD age of 6.0 ± 1.6 years (range 2–10 years; see ESM Table 2). These investigations were approved by the responsible ethics committees.
Serial sections (4 μm) were cut from each pancreas and mounted on glass slides coated in (3-aminopropyl)-triethoxysilane (Sigma). Sections were processed and labelled using a standard immunoperoxidase technique for paraffin sections. HDAC antigens were unmasked by heat-induced epitope retrieval in 10 mmol/l citrate buffer pH 6.0. Primary antibodies (Abcam, Cambridge, UK) were applied for 1 h at room temperature, with the exception of anti-HDAC3, which was incubated overnight at 4°C. Dako REAL Envision Detection System (Dako, Cambridge, UK) was used for antigen detection. An arbitrary scoring system was developed to assess the intensity of staining and the slides were examined and scored independently by two observers. The staining intensity for each of three islets in each case was recorded and mean values were calculated.
To examine the islet cell subtypes producing HDAC isoforms and to confirm their cellular localisation, double immunofluorescence staining was performed. Antisera with specificity for HDAC1, -2 or -3 were incubated as described for the immunoperoxidase method above and were detected with goat Alexa Fluor 568-conjugated secondary antibody (Invitrogen, Paisley, UK). The sections were washed and stained with guinea-pig anti-insulin serum (Dako), detected with a goat anti-guinea-pig secondary antibody conjugated with Alexa Fluor 488. DAPI (1:1,000; Invitrogen) was included in the final secondary incubation. Sections were mounted in Vectashield hard-set mounting medium (Vector, Peterborough, UK) under glass coverslips. Sections were analysed using identical settings and captured using a Nikon Eclipse 80i microscope (Nikon, Kingston upon Thames, UK) and images were overlaid using NIS-Elements BR 3.0 software (Nikon).
Comparisons between groups were carried out either by paired t test or by ANOVA followed by pre-planned post hoc tests.
Cytokine-induced beta cell toxicity is mediated through class I HDACs
The most efficient compounds were class I, IIb and IV HDACi, whereas inhibitors of class IIa HDACs were ineffective (Fig. 1b, ESM Table 3). We next screened six commercially available HDACi (structures shown in ESM Fig. 1), namely HC toxin, CI-994, PCI24781, LAQ824, vorinostat and PCI34051, for which we determined the inhibitory activity on class I, IIb and IV HDACs. HC toxin, CI-994, PCI24781 and LAQ824 all protected against cytokine-induced beta cell death, whereas the HDAC8-selective inhibitor PCI34051 showed no protection (Fig. 1c, ESM Table 4), a finding verified using two other HDAC8 selective inhibitors (ITF-T, Fig. 1, ESM Table 3, and data not shown). CI-994, a highly selective HDAC1-3 inhibitor, had the highest rescue efficacy. HC toxin, ranking second in rescue efficacy, did not inhibit HDAC6.
These results suggest that the class I HDACs HDAC1, -2 and/or -3 mediate cytokine-induced beta cell toxicity and these HDACs were thus chosen for further knock-down studies.
Knock-down of HDAC1, -2 or -3 decreases cytokine-induced iNos mRNA expression, but only knock-down of HDAC1 and -3 reduces cytokine-induced apoptosis
We generated stable INS-1 clones deficient in HDAC1, -2 or -3 (ESM Fig. 2). As shown in ESM Fig. 2a–c there was a significant increase in the mRNA expression of both Hdac1 and -3 in cells deficient in HDAC2; of note this did not translate into changes in protein levels. Deficiency of HDAC1 and -3 significantly reduced the expression of Hdac2 mRNA (ESM Fig. 2b), while HDAC2 protein levels appeared upregulated in HDAC1-deficient cells (ESM Fig. 2d, f), in line with previous observations [20, 21]. These data suggest interdependent regulation of HDAC expression, as previously observed with pharmacological inhibition .
The INS-1 clones with the most efficient knock-down were selected for further studies (ESM Fig. 2). Knock-down of HDAC1 and -3 significantly protected INS-1 cells from cytokine-induced apoptosis by 38% and 41%, respectively (Fig. 2b, d), whereas knock-down of HDAC2 showed no effect (Fig. 2c).
Cytokine-induced toxicity is mediated by HDAC1 and -3, and knock-down of HDAC1 completely restores insulin secretion in dispersed primary rat islets
Differential roles of HDAC1–3 on NFκB
HDAC1, -2 or -3 knock-down differentially alters cytokine-induced expression of pro-inflammatory mediators
We recently showed that the broad HDAC inhibitor givinostat decreased cytokine-induced beta cell expression of several pro-inflammatory mediators (Il1α, Il1β, Tnfα and Cxcl2) .
Since only HDAC3-mediated cytokine-induced iNos expression depended on NFκB–DNA binding, we wished to test whether a similar differential effect of HDAC1–3 could be demonstrated for other inflammatory mediators typically regulated by NFκB activity.
Islet HDAC1–3 expression in pancreatic sections from children without diabetes and children with recent-onset type 1 diabetes
The islet production of HDAC1 was markedly increased in pancreas sections from five age-matched patients with recent-onset type 1 diabetes (Fig. 6b). Dual immunofluorescence labelling demonstrated that this enzyme was upregulated in the beta cells in type 1 diabetes (Fig. 6d) since it was barely detectable by this method in the insulin-positive cells of controls without diabetes (Fig. 6c). Some immune cells also stained positively for HDAC1 in the inflamed islets of patients with type 1 diabetes, although with a nuclear distribution (Fig. 6d, indicated by arrows). Labelling of HDAC2 and HDAC3 was significantly reduced in the islets of patients with recent-onset type 1 diabetes compared with controls (Fig. 6b). This reduction was not due to the loss of insulin-containing beta cells since staining was also reduced in those islets that retained insulin positivity (Fig. 6d).
There is accumulating evidence that HDACs may be novel pharmacological targets in immune-mediated beta cell destruction leading to type 1 diabetes. Thus, HDACi, such as givinostat, vorinostat and trichostatin A, reduce cytokine-induced beta cell toxicity and restore insulin secretion in vitro and in vivo [12, 14, 15, 22, 24]. However, all HDACi in current clinical use are non-selective, and it is not known which of the 11 HDACs produced by the beta cell  mediate the toxic effects of cytokines. Using 19 HDACi with selectivity for different HDACs we identified HDAC1, -2 and -3 as potential cytokine-regulated targets in beta cells. Specific knock-down of HDAC1 and -3, but not HDAC2, reduced cytokine-induced apoptosis and iNos expression whereas only knock-down of HDAC3 altered the binding of NFκB to the iNos promoter. Furthermore, HDAC1, -2 and -3 differentially regulated beta cell expression of four cytokine-induced pro-inflammatory cytokines. Interestingly, only knock-down of HDAC1 restored the inhibited insulin secretion in primary cells exposed to cytokines. Finally, we examined the levels of HDAC1–3 in pancreases from patients with type 1 diabetes and from control participants and found HDAC1 to be upregulated and located in the beta cell cytosol in diabetic children whereas HDAC2 and -3 were both downregulated and confined to the nucleus.
The striking consistency between the experiments using HDACi and lentiviral knock-down of selected HDACs in both an insulin-producing cell line and dispersed primary rat islet cells strengthen these observations. First, the important protective effect of knocking down HDAC1 and -3 was demonstrated in both models. Second, the reduction of cytokine-induced beta cell apoptosis in the cell line and the primary cells was identical for both HDAC1 (38% and 40%, respectively) and -3 (41% and 42%, respectively). Only the effect of knocking down HDAC2 on cytokine-induced INS-1 cell iNos expression was not confirmed in primary islet cells. This may result from differences in differentiation between the two model systems as described previously [25, 26].
A compelling effect of HDAC inhibition is the ability to restore accumulated insulin release in the beta cell [12, 14], an action mimicked by HDAC1 knock-down in primary islets cells. Indeed, at low glucose concentrations HDAC1 interacts with PDX-1, a transcription factor decisive for the maintenance of the insulin-secreting phenotype of pancreatic beta cells, and this interaction reduces insulin gene expression in insulin-producing MIN6 cells [27, 28].
An intriguing finding was that HDAC1 and -2, but not HDAC3, deficiency reduced cytokine-induced expression of Il1α, Il1β and Tnfα, whereas HDAC3, and to some extent HDAC2, deficiency reduced NFκB–iNos promoter binding. These data illustrate three important points: (1) HDAC1, -2 and -3 regulate constitutive and cytokine-induced gene expression in a distinct manner; (2) cytokine-induced beta cell mRNA expression of Il1α, Il1β and Tnfα is dispensable for cytokine-induced beta cell apoptosis; (3) HDAC1 regulates pro-inflammatory gene expression, including iNos, independently of NFκB–DNA-binding, probably by interfering with NFκB signalling at a more proximal level (e.g. by affecting co-factor binding to p65 or by targeting alternative transcription factors) . Thus, HDAC1–3 all form complexes with the p65 subunit and regulate NFκB-mediated genes in non-beta cells, but only HDAC3 actually deacetylates p65 [6, 30, 31].
Despite considerable homology between HDAC1 and -2 in terms of structure and protein-interaction partners , we found distinct effects of HDAC1 or -2 deficiency on basal- and cytokine-induced gene expression, apoptosis and insulin secretion. Similarly, HDAC1 and -2 differentially regulate stem cell differentiation , extracellular signal-related kinase (ERK)/mitogen-activated protein kinase (MAPK) apoptotic cytokine signalling  and TGF-β-accelerated diabetic nephropathy .
Importantly, HDACs also play a vital role in the development of the endocrine pancreas. Thus inhibition of class IIa HDACs increases the beta/delta cell mass, whereas inhibition of class I HDACs supports alpha/PP cell expansion [34, 35]. These observations warrant future development of class IIa selective HDACi for beta cell differentiation-based therapies and HDAC1- and HDAC3-selective HDACi in anti-inflammatory-based strategies.
We have previously reported that cytokines downregulate HDAC1–3 expression in primary rat islets and HDAC1 and -2 in human islets in vitro . Here we show that HDAC2 and -3 levels are downregulated in islet cells in children with recent-onset type 1 diabetes, possibly reflecting a secondary protective response to inflammatory assault, although it should be recognised that their activity may well be higher compared with healthy individuals. Hence, selective HDACi hold therapeutic promise both before and after disease onset.
Interestingly, not only the production but also the cellular compartmentalisation determines the pathologic actions of HDAC1. Thus, through a newly identified Nuclear Export Signal  HDAC1 is translocated from the nucleus to the cytoplasm in human neurons and impairs axonal transport, restored by preventing HDAC1 shuttling. Therefore, the cytoplasmic localisation of HDAC1 observed in the islets of patients with type 1 diabetes may be a pathological response contributing to pro-apoptotic signalling and impairment of insulin secretion.
Our study further strengthens the notion that HDACi should not only be considered as antineoplastic therapies, but also as potential treatments for inflammatory disorders such as diabetes as reviewed elsewhere [36, 37]. Similar anti-inflammatory properties have been demonstrated in lipopolysaccharide-stimulated human peripheral blood mononuclear cells , an animal model of rheumatoid arthritis  and patients suffering from systemic-onset juvenile idiopathic arthritis (SOJIA) . Importantly, a class I HDAC inhibitor was superior as an anti-rheumatic therapy compared with a pan-inhibitor, further underscoring the role of class I HDACs in inflammatory disorders . In addition, the HDAC inhibitor sodium phenylbutyrate (PBA) increased the insulin sensitivity in NEFA- and triacylglycerol-infused patients , confirming earlier reports showing that PBA reduces endoplasmic reticulum (ER) stress and restores glucose homoeostasis in an animal model of type 2 diabetes mellitus . PBA is also a chemical chaperone that protects cells by reducing ER stress. Alternatively the protective effect of PBA could be exerted by inhibiting the deleterious effects of cytokines produced by macrophages in response to NEFA-induced beta cell macrophage chemoattractant production . HDAC knock-down may reveal the mechanisms by which PBA ameliorates NEFA-induced beta cell demise.
In conclusion HDAC1, -2 and -3 have distinct pathologic functions in the beta cell. In vitro, HDAC1 and -3 are each required for cytokine-induced beta cell death, whereas HDAC1 also selectively impairs insulin secretion. Conversely only HDAC3 appears to be involved in cytokine-induced NFκB DNA binding. In the beta cells of children with type 1 diabetes, HDAC1 was upregulated and was localised in the cytosol, whereas HDAC2 and -3 were localised to the nucleus and were downregulated. These findings suggest that targeting HDAC1 and HDAC3 should provide optimal protection of beta cell mass and function in clinical islet transplantation and in patients with recent-onset type 1 diabetes.
We thank D. Trono (Tronolab, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Switzerland) for providing the envelope, package and empty vector plasmids. G. K. Singh (Center for Medical Research Methodology, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark) is thanked for technical assistance.
This work was supported by JDRF (grant no. 26-2008-893), NIH (AI-15614 and AR-45584), The IL-1 Foundation, a University of Copenhagen career PhD fellowship, a Novo Nordisk STAR Postdoc fellowship, Diabetes Research and Wellness Foundation and the Novo Nordisk Foundation.
Duality of interest
P. Mascagni and A. Stevenazzi are employed by Italfarmaco. All other authors declare that there is no duality of interest associated with this manuscript.
ML, LGG, NGM and TMP planned and designed the study. CAD, AS and PM synthesised and performed HDAC activity assays of the ITF inhibitors. TS and JB carried out HDAC activity assays for the commercially available HDACi. SJR and NGM were responsible for histological analyses. All other experimental work was carried out by ML, DPC, MDN and MSD. ML and TMP wrote the first draft of the manuscript, which was commented on by all authors. ML, DPC, MSD and TMP edited the final manuscript. All authors approved the final version. TMP is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.